15. Inclusion body myositis Clinical trials / Disease details
Clinical trials : 42 / Drugs : 33 - (DrugBank : 11) / Drug target genes : 12 - Drug target pathways : 123
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05721573 (ClinicalTrials.gov) | February 28, 2023 | 1/2/2023 | A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis | A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of ABC008 in the Treatment of Subjects With Inclusion Body Myositis | Inclusion Body Myositis | Drug: ABC008 | Abcuro, Inc. | Syneos Health | Recruiting | 40 Years | N/A | All | 231 | Phase 2/Phase 3 | United States |
| 2 | NCT04659031 (ClinicalTrials.gov) | May 25, 2021 | 25/11/2020 | A Phase 1 Study of ABC008 in Ascending (Single Ascending Dose/Multiple Ascending Dose) Study in Patients With (IBM) | A Phase 1, Open-Label, Ascending Dose Study of ABC008 in Adult Patients With Inclusion Body Myositis (IBM) | Inclusion Body Myositis | Drug: ABC008 | Abcuro, Inc. | NULL | Recruiting | 40 Years | N/A | All | 30 | Phase 1 | Australia |